TYRX, developer of implantable medical devices designed to help reduce surgical-site infections associated with cardiovascular implantable electronic devices (CIEDs) including pacemakers and implantable defibrillators, has announced that Frost & Sullivan has named the AIGISRx Antibacterial Envelope as the recipient of its New Product Innovation Award for 2012.
“To date TYRX’s AIGISRx is very unique in the fact that it is the first and only antibacterial product of its kind to receive US Food and Drug Administration (FDA) clearance. The product not only helps in stabilising the pacemaker or ICD, but it also helps reduce infection by delivering antibiotics directly to the surgical site in the first 7 to 10 days following implantation,” said Darshana De, IP and Best Practices analyst from Frost & Sullivan.
The AIGISRx Antibacterial Envelope is designed to address surgical-site infections which are expensive to treat and have a significant impact on patients and hospitals.
Patients suffering from surgical-site infections following CIED procedures:
- spend an average of two extra weeks in the hospital
- undergo repeat surgical procedures to treat the infection
- cost the facility an average of US$72,485
- experience significant increases in morbidity and mortality, with one-year mortality rates of 26.5% to 35.1%, depending on device type
The recipient of the Frost & Sullivan New Product Innovation Award is selected after rigorous analysis of industry’s leading companies who demonstrate outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development.
“Since TYRX was founded, we have been working diligently to research, develop, and commercialise technologies which help reduce surgical-site infections and improve patient outcomes,” said Robert White, president and CEO of TYRX. “Our team appreciates Frost & Sullivan’s acknowledgement of our product leadership and innovation.”
